Matrix metalloproteinases and inflammatory mediators (MMPs and inflammatory mediators)

Matrix metalloproteinases (MMPs) and inflammatory mediators represent a complex network of enzymes and signaling molecules that regulate tissue homeostasis and the immune response. MMPs are a family of zinc-dependent endopeptidases, such as MMP-2 and MMP-9, primarily responsible for the degradation and remodeling of the extracellular matrix (ECM) [1]. Inflammatory mediators include a diverse array of molecules like cytokines (e.g., TNF-alpha, IL-1-beta), chemokines, and prostaglandins that initiate and amplify inflammatory cascades [2]. In pathological states like rheumatoid arthritis and cancer, inflammatory mediators often trigger the overexpression of MMPs, leading to accelerated tissue destruction and facilitating tumor metastasis [3]. While specific components of this axis are targeted by drugs—such as TNF inhibitors or broad-spectrum MMP inhibitors—the term itself describes a biological pathway or a group of targets rather than a single discrete therapeutic target [4]. Consequently, therapeutic strategies often focus on specific members of these families to minimize off-target effects and systemic toxicity [5]. Sources: [1] Jabłońska-Trypuć et al. (2016) J Enzyme Inhib Med Chem; [2] Turner et al. (2014) BBA - Mol Cell Res; [3] Manicone & McGuire (2008) Semin Cell Dev Biol; [4] Fields (2019) Cells; [5] Vandenbroucke & Libert (2014) Nat Rev Drug Discov.

Other names

MatrixinsPro-inflammatory cytokinesChemokinesInflammatory signaling moleculesECM degrading enzymes

Inhibition of zinc-dependent proteolytic activity of MMPs and neutralization or inhibition of the synthesis of pro-inflammatory signaling molecules such as TNF-alpha and IL-6.